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Purpose of the study
Previous analyses of the 2 BENCHMRK studies of ralte-
gravir (RAL) vs placebo (Pbo) plus optimized back-
ground therapy (OBT) in treatment-experienced HIV-
infected patients (pts) by PSS as contributed by OBT
used assumptions of susceptibility to DRV/r based on
prior use, since commercial phenotyping was not avail-
able. Re-analysis is now performed using newly available
DRV/r phenotype data.
Methods
In BENCHMRK pts who used DRV/r in OBT, baseline
PSS was recalculated using the DRV/r PhenoSense®
result (Monogram Bioscience). A new analysis by PSS
score of RNA <50c/mL for wk 48 and wk 156 was per-
formed using the upper clinical cutoff (UC) of OBTs,
including DRV/r. An exploratory analysis compared
outcomes for pts whose only fully active ART was RAL
or DRV/r.
Results
184 pts in the RAL group and 99 in Pbo group used
DRV/r in OBT at study entry; of these 166 and 90 pts,
respectively, had no prior use of DRV/r and were pre-
viously considered DRV/r susceptible. 165 pts in the
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Phenosense results: 7% and 7% of pts previously
assumed susceptible to DRV/r showed phenotypic resis-
tance; 17% and 44% assumed resistant to DRV/r were
found to be susceptible.
Overall results at wk 48 were 64% vs 34% with
RNA<50c/mL for RAL vs Pbo. Wk 48 virologic out-
comes by PSS score are shown in table 1. Wk 156 out-
comes by PSS were consistent (not shown). In the
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Table 1
Efficacy at week 48, RNA<50 copies/mL %, (n/N)
Initial approach New analysis
(DRV/r phenotype assumed) (DRV/r phenotype data)
PSS RAL Placebo RAL Placebo
0 51 (17/33) 8 (1/12) 52 (16/31) 8 (1/13)
1 48 (34/71) 13 (7/54) 45 (34/79) 15 (8/55)
2 67 (107/160) 30 (26/88) 69 (102/148) 29 (24/83)
≥3 73 (112/153) 60 (39/65) 72 (113/156) 59 (38/64)
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with RAL (PSS=0) vs DRV/r (Pbo, PSS=1) at wk 48:
52% vs 30% of pts had vRNA <50 c/mL. Wk 156 results
(not shown) were consistent with wk 48.
Conclusions
In BENCHMRK, prior use of DRV predicted DRV sus-
ceptibility similarly to the UC phenotypic criteria. Re-
analysis of virologic responses by PSS score incorporat-
ing the UC Phenosense result for DRV/r demonstrated
consistent treatment differences between RAL and Pbo
groups for all PSS scores, generally similar to the earlier
analyses. In an exploratory analysis approximating a
direct comparison of RAL vs DRV/r as sole active
agents, virologic responses using UC appeared higher
for RAL than DRV at both time points, although num-
bers of pts receiving DRV monotherapy were small.
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